Seres Therapeutics
Clinical-stage biotechnology company focused on development of rationally selected live bacterial consortia as therapeutic medicines. Activities include discovery and development of microbiome-targeted therapeutics, clinical development across infectious and immune/inflammatory indications, manufacturing and CMC process development for live biotherapeutics, regulatory submissions and commercialization experience.
Industries
Nr. of Employees
medium (51-250)
Seres Therapeutics
Cambridge, Massachusetts, United States
Patents
Synergistic bacterial compositions and methods of production and use thereof
US-12409197-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-12083151-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11918612-B2
View Details
Synergistic bacterial compositions and methods of production and use thereof
US-12409197-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-12083151-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11918612-B2
View DetailsProducts
Oral live biotherapeutic for prevention of recurrent Clostridioides difficile infection (commercialized; rights divested)
An approved oral spore-based live biotherapeutic developed to reduce recurrence of C. difficile infection in adults; later divested to a third party.
Oral live biotherapeutic for prevention of recurrent Clostridioides difficile infection (commercialized; rights divested)
An approved oral spore-based live biotherapeutic developed to reduce recurrence of C. difficile infection in adults; later divested to a third party.
Services
Policy and program to provide investigational live biotherapeutic access under defined criteria.
Research collaborations with academic centers and non-profits to define microbiome signatures, enable patient access and advance development of live biotherapeutics.
Policy and program to provide investigational live biotherapeutic access under defined criteria.
Research collaborations with academic centers and non-profits to define microbiome signatures, enable patient access and advance development of live biotherapeutics.
Expertise Areas
- Microbiome therapeutics development
- Clinical trial management for infectious and immune-mediated indications
- Bioprocessing and CMC for live biotherapeutics
- Regulatory strategy and BLA submissions
Key Technologies
- Live bacterial consortium therapeutics
- Microbial genomics and metagenomics
- Bioinformatics and computational biology
- Upstream and downstream bioprocessing
News & Updates
Company led development and obtained FDA approval (April 2023) for an oral live biotherapeutic to prevent recurrence of C. difficile infection in adults.
Sale of commercial rights for the approved oral live biotherapeutic to a third party; transaction completed September 30, 2024.
Phase 1b placebo-controlled study (NCT04995653) in allo-HSCT patients reported reductions in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia through day 100 compared to placebo.
Investigational program received Breakthrough Therapy designation and Fast Track designation for specific indications related to reducing bloodstream infections and graft-versus-host disease risk in allo-HSCT patients.
Company led development and obtained FDA approval (April 2023) for an oral live biotherapeutic to prevent recurrence of C. difficile infection in adults.
Sale of commercial rights for the approved oral live biotherapeutic to a third party; transaction completed September 30, 2024.
Phase 1b placebo-controlled study (NCT04995653) in allo-HSCT patients reported reductions in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia through day 100 compared to placebo.
Investigational program received Breakthrough Therapy designation and Fast Track designation for specific indications related to reducing bloodstream infections and graft-versus-host disease risk in allo-HSCT patients.